Last reviewed · How we verify
ragweed
At a glance
| Generic name | ragweed |
|---|---|
| Sponsor | Cuneyt M. Alper |
| Drug class | Non-Standardized Pollen Allergenic Extract [EPC] |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Swelling
- Erythema
- Pruritus
- Tenderness
- Pain
- Systemic reactions
- Generalized skin erythema
- Urticaria
- Angioedema
- Rhinitis
- Wheezing
- Laryngeal edema
Serious adverse events
- Shock
- Fatal systemic reactions
Key clinical trials
- Study of Indoor Air Pollutants and Their Impact in Children's Health and Wellbeing (NA)
- Study of BLU-808 in Allergic Rhinoconjunctivitis (PHASE2)
- Microglia Activation in Asthma
- Ambrosia: Evaluating the Effects of a Food-As-Medicine Platform on Gut Microbiome Composition and Metabolism (NA)
- Microbiota-Inflammation-Brain Axis in Heart Failure: New Functional Food for the Prevention of undeRnutrition in Older (NA)
- Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis (NA)
- A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis (PHASE2)
- Vestibular Versus Sublingual Route of AIT Tablets (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ragweed CI brief — competitive landscape report
- ragweed updates RSS · CI watch RSS
- Cuneyt M. Alper portfolio CI